奥翔药业：合作产品甲磺酸伊马替尼片获药品注册证书

Core Viewpoint - Aoxiang Pharmaceutical (603229) announced that its wholly-owned subsidiary, Qizheng Pharmaceutical, received the drug registration certificate for Imatinib Mesylate Tablets from the National Medical Products Administration, marking a significant milestone in its collaboration with STADA for the development and commercialization of this product [1] Group 1 - The drug Imatinib Mesylate Tablets is the world's first targeted molecular therapy for cancer, specifically used for treating patients with chronic myeloid leukemia (CML) in the blast phase, accelerated phase, or chronic phase after failure of alpha-interferon therapy [1] - It is also indicated for patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) [1]